Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FTLFNASDAQ:GLSINASDAQ:KRRONASDAQ:KZR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFTLFFitLife Brands$13.32-2.3%$14.27$9.83▼$17.75$128M0.8117,529 shs8,451 shsGLSIGreenwich LifeSciences$8.90-0.2%$9.59$8.06▼$18.15$119.25M1.6946,134 shs33,040 shsKRROKorro Bio$12.35-0.9%$14.60$10.29▼$98.00$117.01M2.45110,736 shs131,615 shsKZRKezar Life Sciences$4.52+1.3%$4.29$3.62▼$9.18$32.58M0.5856,498 shs63,758 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFTLFFitLife Brands-2.27%-4.86%-4.17%-1.19%-3.79%GLSIGreenwich LifeSciences-0.22%-3.26%-8.53%-19.89%-44.27%KRROKorro Bio-0.88%-8.79%-16.55%-48.02%-63.25%KZRKezar Life Sciences+1.35%-1.53%+12.72%-23.26%-30.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFTLFFitLife Brands4.1831 of 5 stars3.73.00.00.01.93.33.1GLSIGreenwich LifeSciences1.9827 of 5 stars3.51.00.00.00.03.30.0KRROKorro Bio1.9157 of 5 stars3.63.00.00.01.10.00.6KZRKezar Life Sciences4.2421 of 5 stars3.25.00.04.60.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFTLFFitLife Brands 3.33Buy$20.5053.90% UpsideGLSIGreenwich LifeSciences 3.00Buy$39.00338.20% UpsideKRROKorro Bio 3.29Buy$102.43729.38% UpsideKZRKezar Life Sciences 2.33Hold$39.50773.89% UpsideCurrent Analyst Ratings BreakdownLatest KZR, KRRO, FTLF, and GLSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.005/13/2025KRROKorro BioOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$155.00 ➝ $90.005/8/2025KRROKorro BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$115.00 ➝ $100.004/29/2025KRROKorro BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025KRROKorro BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$74.004/21/2025GLSIGreenwich LifeSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$38.00 ➝ $39.004/16/2025KRROKorro BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$25.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFTLFFitLife Brands$64.47M1.94$0.99 per share13.45$3.93 per share3.39GLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.19 per shareN/AKRROKorro Bio$2.27M51.09N/AN/A$17.12 per share0.72KZRKezar Life Sciences$7M4.72N/AN/A$16.02 per share0.28Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFTLFFitLife Brands$8.98M$0.8415.8612.11N/A13.85%25.59%15.26%N/AGLSIGreenwich LifeSciences-$15.79M-$1.26N/AN/AN/AN/A-450.87%-333.18%8/12/2025 (Estimated)KRROKorro Bio-$83.58M-$9.44N/AN/AN/AN/A-51.64%-37.94%8/12/2025 (Estimated)KZRKezar Life Sciences-$83.74M-$10.82N/AN/AN/AN/A-61.15%-50.27%8/12/2025 (Estimated)Latest KZR, KRRO, FTLF, and GLSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025GLSIGreenwich LifeSciences-$0.24-$0.25-$0.01-$0.25N/AN/A5/15/2025Q1 2025FTLFFitLife Brands$0.24$0.20-$0.04$0.20N/AN/A5/13/2025Q1 2025KZRKezar Life Sciences-$2.56-$2.27+$0.29-$2.27N/AN/A5/7/2025Q1 2025KRROKorro Bio-$2.60-$2.49+$0.11-$2.49$0.13 million$2.55 million4/15/2025Q4 2024GLSIGreenwich LifeSciences-$0.21-$0.61-$0.40-$0.61N/AN/A3/27/2025Q4 2024FTLFFitLife Brands$0.22$0.21-$0.01N/AN/AN/A3/25/2025Q4 2024 & Study ResultKZRKezar Life Sciences-$2.71-$2.77-$0.06-$2.77N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFTLFFitLife BrandsN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/AKRROKorro BioN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFTLFFitLife Brands0.191.640.72GLSIGreenwich LifeSciencesN/A1.911.91KRROKorro BioN/A9.419.41KZRKezar Life Sciences0.047.097.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFTLFFitLife Brands2.32%GLSIGreenwich LifeSciences4.16%KRROKorro Bio13.18%KZRKezar Life Sciences67.90%Insider OwnershipCompanyInsider OwnershipFTLFFitLife Brands61.30%GLSIGreenwich LifeSciences51.67%KRROKorro Bio4.60%KZRKezar Life Sciences10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFTLFFitLife Brands209.39 million3.63 millionNot OptionableGLSIGreenwich LifeSciences313.37 million6.46 millionNot OptionableKRROKorro Bio709.39 million8.96 millionNo DataKZRKezar Life Sciences607.31 million6.55 millionNot OptionableKZR, KRRO, FTLF, and GLSI HeadlinesRecent News About These CompaniesKezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?May 27, 2025 | zacks.comKezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | businesswire.comKezar toplines small Phase 2a dataset in autoimmune liver diseaseMarch 27, 2025 | endpts.comKezar Life Sciences price target lowered to $7 from $9 at Wells FargoMarch 27, 2025 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Roche Holding AG (OtherRHHVF), Kezar Life Sciences (KZR) and Axsome Therapeutics (AXSM)March 26, 2025 | markets.businessinsider.comKezar Life Sciences reports topline results from PORTOLA trialMarch 26, 2025 | markets.businessinsider.comKezar Life Sciences, Inc. (KZR) PORTOLA Topline Phase 2a Results in Autoimmune Hepatitis Conference Call (Transcript)March 25, 2025 | seekingalpha.comKezar drops after Q4 results and mid-stage data for lead assetMarch 25, 2025 | msn.comKezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial ResultsMarch 25, 2025 | businesswire.comKezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025March 24, 2025 | businesswire.comTD Cowen Keeps Their Buy Rating on Kezar Life Sciences (KZR)February 28, 2025 | markets.businessinsider.comPositive Report for Kezar Life Sciences (KZR) from William BlairFebruary 28, 2025 | markets.businessinsider.comWilliam Blair Sticks to Its Hold Rating for Kezar Life Sciences (KZR)February 25, 2025 | markets.businessinsider.comKezar Life Sciences files $400M mixed securities shelfFebruary 6, 2025 | markets.businessinsider.com(KZR) Investment AnalysisJanuary 1, 2025 | news.stocktradersdaily.comKezar Life Sciences price target lowered to $9 from $11 at Wells FargoDecember 19, 2024 | markets.businessinsider.comTrend Tracker for (KZR)December 10, 2024 | news.stocktradersdaily.comKezar Life Sciences updates shareholder rights agreementDecember 5, 2024 | investing.comKezar Life Sciences (KZR) Receives a Hold from H.C. WainwrightDecember 2, 2024 | markets.businessinsider.comWhen the Price of (KZR) Talks, People ListenNovember 20, 2024 | news.stocktradersdaily.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKZR, KRRO, FTLF, and GLSI Company DescriptionsFitLife Brands NASDAQ:FTLF$13.32 -0.31 (-2.27%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$13.37 +0.05 (+0.38%) As of 06/20/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FitLife Brands, Inc. provides nutritional supplements for health-conscious consumers in the United States and internationally. The company provides weight loss, sports nutrition, and general health products; sports nutrition products; weight loss and sports nutrition products; sports nutrition and general wellness formulations with an emphasis on natural, vegan, and organic ingredients; and male health and weight loss products, as well as other diet, health, and sports nutrition supplements and related products; and value-oriented sports nutrition and weight loss products. It offers MRC products which includes general health supplements; and natural skincare and beauty products. In addition, it markets its products under the brand names of NDS Nutrition, PMD Sports, SirenLabs, CoreActive, Nutrology, Metis Nutrition, iSatori, BioGenetic Laboratories, Energize, Dr. Tobias, All-Natural Advice, and Maritime Naturals through franchised stores, as well as through retail locations, which include specialty, mass, and online. The company was formerly known as Bond Laboratories, Inc. and changed its name to FitLife Brands, Inc. in September 2013. FitLife Brands, Inc. was incorporated in 2005 and is headquartered in Omaha, Nebraska.Greenwich LifeSciences NASDAQ:GLSI$8.90 -0.02 (-0.22%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$8.88 -0.03 (-0.28%) As of 06/20/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Korro Bio NASDAQ:KRRO$12.35 -0.11 (-0.88%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$12.37 +0.02 (+0.16%) As of 06/20/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Kezar Life Sciences NASDAQ:KZR$4.52 +0.06 (+1.35%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$4.51 0.00 (-0.11%) As of 06/20/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
